These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37517865)
1. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL; Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865 [TBL] [Abstract][Full Text] [Related]
2. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cuende N; Rasko JEJ; Koh MBC; Dominici M; Ikonomou L Cytotherapy; 2018 Nov; 20(11):1401-1413. PubMed ID: 30366616 [TBL] [Abstract][Full Text] [Related]
3. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453 [TBL] [Abstract][Full Text] [Related]
4. Regulatory Frameworks for Gene and Cell Therapies in Japan. Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217 [TBL] [Abstract][Full Text] [Related]
5. Promoting the ethical use of safe and effective cell-based products: the Andalusian plan on regenerative medicine. Cuende N; Álvarez-Márquez AJ; Díaz-Aunión C; Castro P; Huet J; Pérez-Villares JM Cytotherapy; 2020 Dec; 22(12):712-717. PubMed ID: 32878735 [TBL] [Abstract][Full Text] [Related]
6. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study. Chavez J; Shah NA; Ruoss S; Cuomo RE; Ward SR; Mackey TK Stem Cell Res Ther; 2021 Mar; 12(1):189. PubMed ID: 33736697 [TBL] [Abstract][Full Text] [Related]
7. How do I: Evaluate the safety and legitimacy of unproven cellular therapies? Guleria I; de Los Angeles Muñiz M; Wilgo M; Bapat A; Cui W; Hsu YS; Jeyaraman M; Muthu S; Rodriguez F; Fesnak A; Celluzzi C; Sesok-Pizzini D; Reich-Slotky R; Spitzer T Transfusion; 2022 Mar; 62(3):518-532. PubMed ID: 35143051 [TBL] [Abstract][Full Text] [Related]
8. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives. Bakopoulou A J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189 [TBL] [Abstract][Full Text] [Related]
9. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
10. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Nagai S; Ozawa K Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858 [TBL] [Abstract][Full Text] [Related]
11. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099 [TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
13. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products]. Sato Y Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195 [TBL] [Abstract][Full Text] [Related]
14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
15. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland. Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841 [TBL] [Abstract][Full Text] [Related]
16. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. López-Beas J; Guadix JA; Clares B; Soriano-Ruiz JL; Zugaza JL; Gálvez-Martín P Med Res Rev; 2020 Jul; 40(4):1315-1334. PubMed ID: 32017179 [TBL] [Abstract][Full Text] [Related]
17. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry. Maziarz RT; Arthurs J; Horwitz E Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849 [TBL] [Abstract][Full Text] [Related]
18. Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Viswanathan S; Bubela T Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706 [TBL] [Abstract][Full Text] [Related]
19. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Weiss DJ; Turner L; Levine AD; Ikonomou L Cytotherapy; 2018 Feb; 20(2):165-168. PubMed ID: 29239793 [TBL] [Abstract][Full Text] [Related]
20. Marketing of Unproven and Unapproved Regenerative Medicine Therapies. Rodeo SA Sports Health; 2024; 16(3):312-314. PubMed ID: 38629755 [No Abstract] [Full Text] [Related] [Next] [New Search]